Scinai Immunotherapeutics (SCNI) Return on Capital Employed (2020 - 2026)

Scinai Immunotherapeutics (SCNI) has 6 years of Return on Capital Employed data on file, last reported at 71.24% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed changed N/A year-over-year to 71.24%; the trailing twelve-month figure through Mar 2026 stood at 71.24% (changed N/A YoY), and the FY2025 full-year result was 88.98%, down 2572.0% from the prior year.
• Return on Capital Employed improved to 71.24% in Q1 2026, from 78.18% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 74.37% in Q3 2022 to a low of 87.12% in Q3 2023.
• A 4-year average of 40.67% and a median of 56.62% in 2023 frame the typical range for Return on Capital Employed.
• Peak annual rise in Return on Capital Employed reached 8636 bps in 2023, while the deepest fall reached 16148 bps in 2023.
• Tracing SCNI's Return on Capital Employed over 4 years: stood at 74.94% in 2022, then soared by 115 bps to 11.42% in 2023, then sank by 784 bps to 78.18% in 2024, then grew by 9 bps to 71.24% in 2026.
• Business Quant data shows SCNI's Return on Capital Employed at 71.24% in Q1 2026, 78.18% in Q4 2024, and 67.4% in Q3 2024.